News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
Evotec SE reports challenging H1 2024 results with priority reset for sustainable growth. New CEO accelerates transformation program focusing on core strengths -
-
-
COMMUNIQUÉ DE PRESSE
Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
Evotec SE announces strong progress in strategic partnership with Bristol Myers Squibb for molecular glue degraders, triggering payments of US$75m. Joint pipeline expanding in oncology field